Anti-suicidal Effects of Buprenorphine In Depressed Individuals

NCT05427981 | Withdrawn Phase 3 DMC FDA Drug

• 1 other identifier: IRB #8086
• Study Type: interventional
• Target: N/A
• Locations: 1 country
• Sites: 1

Brief Summary

This study aims to examine the effect of low-dose buprenorphine as an add-on to treatment-as-usual for suicidal ideation in individuals with major depression, and investigate the functional brain activity related to its potential anti-suicidal effect.

Conditions

Suicidal Ideation; Major Depressive Disorder

Outcome Measures

Primary Outcomes (1)

• Changes in Beck Scale for Suicidal Ideation (SSI) scores from pre- to Week 2 post-treatment.

  Clinician-based questionnaire measuring level of suicidal ideas over the last 7 days; 21 items scored 0 to 2; total score ranges from 0 to 38 (last 2 items not counted), higher scores mean more intense suicidal ideas.

  2 Weeks

Secondary Outcomes (1)

• Changes in functional magnetic resonance imaging (fMRI) blood oxygen- level dependent (BOLD) signal in the amygdala in response to negative vs. neutral pictures from pre- to Week 2 post-treatment

  2 Weeks

Study Arms (2)

Buprenorphine

EXPERIMENTAL

Buccal Films

Drug: Belbuca Buccal Product

Placebo

PLACEBO COMPARATOR

Buccal Films

Other: Placebo

Interventions

Belbuca Buccal Product DRUG

Buprenorphine Buccal Films

Buprenorphine

Placebo OTHER

Placebo Buccal Films

Placebo

Eligibility Criteria

• Age: 18 Years - 65 Years
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• In order to be eligible to participate in this study, an individual must meet all of the following criteria:
• Provision of signed and dated informed consent form.
• Stated willingness to comply with all study procedures and availability for the duration of the study.
• Male or female.
• Aged 18-65 years.
• Ability to take oral medication and be willing to adhere to the treatment regimen.
• Current major depressive episode.
• Hamilton Depression Rating Scale (HDRS) Score \> 16.
• Active suicidal ideation (Columbia Suicide Severity Rating Scale (C-SSRS) of 3 or more).
• Participants must have been on a medication regimen for depression that includes an adequate dose of antidepressant for at least the past 4 weeks.

You may not qualify if:

• An individual who meets any of the following criteria will be excluded from participation in this study:
• Current active psychosis or mania.
• Current or past alcohol use disorder or substance use disorder involving any prescribed or any illicit drug (opioid, benzodiazepine, or other drug use) including mild severity.
• Family history of alcohol or substance use disorder in a first-degree relative.
• Current or past history of prescription or non-prescription opioid use.
• History of other risk factors for the development of opioid misuse and opioid use disorder other than comorbid depression (e.g., homelessness, criminal record, aggressive or violent behavior that resulted in injury to another person).
• Current acute or chronic pain.
• Neurological disorders (e.g., epilepsy, brain tumors or patients with increased intracranial pressure due to other reasons).
• A history of prior head trauma with evidence of cognitive impairment. Participants who endorse a history of prior head trauma will be administered the Trail-making A and B test. Those who score 1.5 standard deviations below the mean on the Trail-making A or B will be excluded from study participation.
• Active significant medical illness that would make study participation hazardous to the participant or compromise study findings or would prevent the participant from completing the study (e.g., oral mucositis, orthostatic hypotension, history of hypotensive disorders, hypokalemia, hypomagnesemia, or clinically unstable cardiac disease, including unstable atrial fibrillation, symptomatic bradycardia, unstable congestive heart failure, or active myocardial ischemia, history of Long QT syndrome or immediate family member with this condition, moderate to severe hepatic impairment or hepatitis, liver cirrhosis , severe chronic pulmonary diseases, significant respiratory depression, acute or severe bronchial asthma, known or suspected gastrointestinal obstruction, including paralytic ileus).
• Participants taking medications that prolong the QT interval (e.g., Class IA antiarrhythmic medications (e.g., quinidine, procainamide, disopyramide) or Class III antiarrhythmic medications (e.g., sotalol, amiodarone, dofetilide)).
• Participants taking medications with potentially clinically-significant drug interactions with BELBUCA , including benzodiazepines, central nervous system (CNS) depressants (e.g., alcohol, anxiolytics, general anaesthetics, hypnotics, neuroleptics, phenothiazines, sedatives, tranquilizers), other opioid analgesics, muscle relaxants, diuretics, anticholinergic drugs, non-nucleoside reverse transcriptase inhibitors (e.g., efavirenz, nevirapine, etravirine, delavirdine), protease inhibitors (e.g., atazanavir, ritonavir). Additionally, patients must discontinue CYP3A4 strong inhibitors (e.g., clarithromycin, telithromycin, nefazodone, itraconazole, ketoconazole) 2 weeks before initiation of the study.
• Known allergy or sensitivity to buprenorphine.
• If female, pregnancy, abortion or miscarriage in the previous two months, current breastfeeding or plans to conceive during the course of study participation. Patients who are not on contraceptives will be asked to at least use barrier methods during sexual intercourse. All patients must commit to not attempting to become pregnant during participation in the study.
• Inability to read and speak English fluently.

Sponsors & Collaborators

• New York State Psychiatric Institute: lead

Study Sites (1)

New York State Psychiatric Institute

New York, New York, 10032, United States

Location

MeSH Terms

Conditions

Suicidal Ideation; Depressive Disorder, Major

Condition Hierarchy (Ancestors)

Suicide; Self-Injurious Behavior; Behavioral Symptoms; Behavior; Depressive Disorder; Mood Disorders; Mental Disorders

Study Officials

• Mina M Rizk, MD

  New York State Psychiatric Institute

  PRINCIPAL INVESTIGATOR

• Jeffrey M Miller, MD

  New York State Psychiatric Institute

  PRINCIPAL INVESTIGATOR

Study Design

• Study Type: interventional
• Phase: phase 3
• Allocation: RANDOMIZED
• Masking: DOUBLE
• Who Masked: PARTICIPANT, OUTCOMES ASSESSOR
• Purpose: TREATMENT
• Intervention Model: PARALLEL
• Sponsor Type: OTHER
• Responsible Party: PRINCIPAL INVESTIGATOR
• PI Title: Assistant professor

Study Record Dates

• First Submitted: June 16, 2022
• First Posted: June 22, 2022
• Study Start: October 10, 2022
• Primary Completion: January 14, 2024
• Study Completion: January 14, 2024
• Last Updated: November 14, 2023

Record last verified: 2023-11

Data Sharing

• IPD Sharing: Will not share

Locations

US (1)